证券代码：002589 证券简称：瑞康医药 公告编号：2023-040 本议案以 3 票同意，0 票反对，0 票弃权的表决结果获得通过。 本议案尚需提交公司 2023 年第三次临时股东大会审议。 瑞康医药集团股份有限公司 第五届监事会第三次会议决议的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）第五届监事会第三次会议通 知于 2023 年 8 月 24 日以书面形式发出，2023 年 8 月 29 日上午在烟台市芝罘区 凤鸣路 103 号 13 号楼会议室以现场及通讯表决的方式召开。会议由张岩女士主 持，会议应出席监事 3 名，实际出席监事 3 名。会议的召开符合《中华人民共和 国公司法》和《公司章程》的规定。经与会监事审议，会议形成如下决议： 一、审议通过《关于公司及子公司担保额度预计的议案》 为满足公司及合并报表范围内子公司（以下简称"子公司"）正常的生产经营 需要，确保资金流畅通，同时加强公司及子公司对外担保的日常管理，增强公司 及子公司对外担保行为的计划性和合理性，公司为子公司提供担保、子公司互相 担 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2023-035 瑞康医药集团股份有限公司 关于实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）近日接到实际控制人张仁华 女士的函告，获悉张仁华女士所持有本公司的部分股份已解除质押，具体事项如 下： 公司控股股东未来股份变动如达到《证券法》、《上市公司收购管理办法》 等规定的相关情形的，将严格遵守权益披露的相关规定，及时履行信息披露义务。 四、备查文件 股东名 称 是否为第 一大股东 及一致行 动人 解除质押 股数（万 股） 质押开始 日期 占其所持 股份比例 占公司总 股本比例 质押解除日 期 质权人 张仁华 是 4,132.00 2022 年 02 月 18 日 20.51% 2.75% 2023 年 8 月 7 日 荆州招商慧泽医药 投资合伙企业（有 限合伙） 合 计 - 4,132.00 - 20.51% 2.75% - - 一、本次解除质押的基本情况 二、股东所持股份累计被质押的情况 截至公告披露日，张仁华女士及其一致行 ...

Financial Performance - The total revenue for 2022 was ¥12,311,277,753.66, a decrease of 41.54% compared to ¥21,059,718,896.22 in 2021[25] - The net profit attributable to shareholders was -¥1,831,651,850.30, representing a decline of 1,496.31% from a profit of ¥131,178,285.52 in the previous year[25] - The net profit after deducting non-recurring gains and losses was -¥927,557,877.39, a decrease of 304.30% compared to -¥229,425,703.00 in 2021[25] - Basic earnings per share were -¥1.2424, a decline of 1,480.44% from ¥0.09 in 2021[25] - Total assets at the end of 2022 were ¥18,331,074,646.82, down 30.56% from ¥26,396,974,447.33 at the end of 2021[25] - Net assets attributable to shareholders decreased by 28.53% to ¥5,407,787,638.68 from ¥7,567,035,854.72 in 2021[25] - The company reported a significant uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years[25] - The company reported a significant decline in revenue across all major regions, with Hunan province experiencing a 52.58% drop[68] - The company’s service revenue fell by 64.97% to ¥23.68 million in 2022[69] - The company’s financial assets include derivative financial assets valued at ¥67,002,767, with no impairments recorded[87] Cash Flow and Investments - Operating cash flow net amount increased by 18.09% to ¥523,073,874.41 from ¥442,952,611.75 in 2021[25] - The net cash flow from operating activities was ¥523,073,874.41, an increase of 18.09% compared to the previous year[83] - Cash and cash equivalents increased to ¥5,340,211,821.91, representing 29.13% of total assets, up from 17.35% at the beginning of the year[85] - The total investment amount for the reporting period was ¥456,286,107, representing a 13.33% increase compared to ¥402,624,352.45 in the same period last year[89] - Investment cash inflow surged by 803.57% to ¥2,531,785,150.53, while investment cash outflow increased by 124.48% to ¥1,938,827,766.52[83] Revenue Segmentation - The pharmaceutical and medical device distribution segment achieved total revenue of 8.822 billion yuan during the reporting period[44] - The IVD segment generated sales revenue of 3.246 billion yuan, focusing on providing intelligent and standardized laboratory solutions[47] - The academic services segment reported sales revenue of 75.78 million yuan, serving over 300 medical institutions[48] - The digital healthcare segment achieved sales revenue of 77.20 million yuan, leveraging AI technology for clinical medication management[50] - Revenue from the pharmaceutical equipment segment accounted for 99.19% of total revenue, declining by 41.72% year-over-year[68] - Direct sales contributed 83.57% of total revenue, with a decrease of 40.06% compared to the previous year[69] Strategic Initiatives - The company is actively expanding into innovative traditional Chinese medicine and digital healthcare sectors to establish new growth points[42] - The company plans to optimize product structure and reduce costs to improve efficiency[42] - The company is focusing on cash flow recovery and asset disposal to enhance financial stability[42] - The company aims to accelerate the innovation and commercialization of traditional Chinese medicine (TCM) products, including health foods and dietary supplements, to enhance production and sales scale[100] - The company will strengthen strategic cooperation with universities and research institutions to develop new TCM extracts and high-end products, exploring new markets and growth points[100] Management and Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and decision-making[110] - The board of directors consists of nine members, including three independent directors, ensuring compliance with regulatory requirements[112] - The company maintains independence from its controlling shareholders in terms of business, assets, personnel, and finance, ensuring no conflicts of interest[120][122] - The company has established an independent financial department with a complete financial accounting system, ensuring financial independence and compliance[125] - The company has implemented a comprehensive investor relations management system to ensure fair treatment of all investors and timely information disclosure[179] Human Resources and Employee Engagement - The total number of employees at the end of the reporting period was 5,118, with 647 in the parent company and 3,092 in major subsidiaries[158] - The professional composition includes 2,020 sales personnel, 598 technical staff, and 242 production personnel[159] - The company has established a comprehensive salary and benefits system, along with a performance evaluation system to attract and retain talent[160] - The training program includes topics such as corporate culture, leadership, and quality management, tailored to employees' career development plans[161] - The employee stock ownership plan involved 108 employees holding a total of 30,398,300 shares, representing 2.02% of the company's total equity[164] Future Outlook and Challenges - The company plans to focus on expanding hospital distribution rights and channel sales in advantageous regions to optimize product structure and improve gross margins[99] - The company faces risks from policy changes in the healthcare sector, including price reductions and procurement policy adjustments, which may impact profitability[102] - The company aims to maintain a proactive approach to adapting to market changes and government policies to guide its operational strategies[102] - The company is actively pursuing high-end medical equipment production, traditional Chinese medicine innovation, and medical information technology (SAAS) products through self-research and external investments[104] - The company is facing management risks due to the need for higher management standards across procurement, production, R&D, sales, finance, quality, and internal control[106]

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,073,027,669.16, a decrease of 49.36% compared to ¥4,093,497,042.67 in the same period last year[5] - The net profit attributable to shareholders was ¥21,159,565.23, down 50.49% from ¥42,736,596.17 year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥4,256,424.09, representing a decline of 111.08% compared to ¥38,429,500.10 in the previous year[5] - Basic earnings per share were ¥0.014, down 50.00% from ¥0.028 year-on-year[5] - Net profit for Q1 2023 was CNY 32,936,581.69, compared to CNY 146,001,703.08 in the same period last year, indicating a decrease of 77.5%[22] - The net profit for Q1 2023 was CNY 29,983,448.04, a decrease of 69.6% compared to CNY 98,579,158.25 in the same period last year[23] Cash Flow - The net cash flow from operating activities decreased by 42.36% to ¥75,590,663.40 from ¥131,152,117.17 in the same period last year[5] - Cash inflow from operating activities totaled CNY 2,428,371,185.81, a decrease of 51% from CNY 4,954,931,079.23 in the previous year[25] - The net cash flow from operating activities was CNY 75,590,663.40, down 42.5% from CNY 131,152,117.17 in Q1 2022[25] - Cash flow from investing activities showed a net inflow of CNY 247,712,308.90, compared to a net outflow of CNY 275,361,878.78 in the same period last year[26] - Cash flow from financing activities resulted in a net inflow of CNY 57,982,031.64, an increase from CNY 31,077,571.00 in Q1 2022[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥19,189,860,338.12, an increase of 4.68% from ¥18,331,074,646.82 at the end of the previous year[5] - Total current assets increased to CNY 13,947,004,834.98 from CNY 12,819,555,974.53, representing an increase of 8.8%[20] - Total non-current assets decreased to CNY 5,242,855,503.14 from CNY 5,511,518,672.29, reflecting a decline of 4.9%[20] - Total liabilities increased to CNY 13,399,986,928.74 from CNY 12,579,267,518.31, marking an increase of 6.5%[20] - Total equity increased to CNY 5,789,873,409.38 from CNY 5,751,807,128.51, showing a growth of 0.7%[20] Operational Costs - Total operating costs for Q1 2023 were CNY 2,081,916,966.47, down from CNY 3,955,744,878.12, reflecting a reduction of 47.5%[22] - Cash received from sales and services decreased by 51.65% to 224.28 million compared to the same period last year[13] - Cash paid for purchasing goods and services decreased by 42.26% to 211.71 million, reflecting a reduction in sales revenue[13] - Cash paid to employees decreased by 57.17% to 7.63 million, indicating a significant reduction in workforce-related expenses[13] - Cash paid for taxes decreased by 78.53% to 3.86 million, attributed to lower tax obligations compared to the previous year[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 100,246[15] - The top shareholder, Zhang Renrong, holds 14.39% of shares, amounting to 216.50 million shares, with a significant portion pledged[15] Miscellaneous - The company reported a significant increase in investment income of 1,837,627.59% to ¥5,328.83 due to the divestiture of a subsidiary[11] - Short-term borrowings increased by 42.77% to ¥548,213.68 from ¥383,983.47 at the beginning of the year[10] - The company’s research and development expenses decreased by 33.46% to ¥284.67 from ¥427.85 in the previous year[11] - The company’s total liabilities decreased by 62.95% in long-term borrowings to ¥2,490.00 from ¥6,720.00 due to repayment[10] - The company did not conduct an audit for the Q1 2023 report[27] - The report was released on April 29, 2023[28]

证券代码：002589 证券简称：瑞康医药 公告编号：2023-023 瑞康医药集团股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日在巨 潮资讯网（www.cninfo.com.cn）上披露了 2022 年年度报告全文及其摘要。为进 一步加强公司与投资者的沟通交流，建立良好沟通机制，让广大投资者能深入了 解公司经营情况、未来发展战略等，公司拟举办 2022 年年度业绩说明会（以下 简称"业绩说明会"）。 登录深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入"云访谈" 栏目，或扫描下方二维码，参与本次业绩说明会。 二、公司出席人员 公司拟出席本次业绩说明会的人员有：公司董事长韩旭先生，董事会秘书周 云女士，财务负责人冯芸女士，独立董事于建青先生。 三、投资者问题征集 为充分尊重投资者、提升交流的针对性，现就本次业绩说明会提前向投资者 公开征集问题，广泛听取投资者的意见和建议。公司欢迎广大投资者 ...

Group 1: Company Growth - Revenue reached 5.602 billion yuan, with a net profit of 129 million yuan, representing year-on-year growth of 27.30% and 29.58% respectively [1] - The growth in pharmaceutical sales is attributed to the improvement of the company's sales network and strong terminal coverage capabilities [1] Group 2: Profitability Metrics - Gross profit margin increased by 0.47 percentage points due to a higher proportion of high-margin consumable distribution business [1] - Selling expense ratio rose by 0.35 percentage points to 5.11%, driven by increased sales expenses corresponding to revenue growth and expansion in the medical device business [1] Group 3: Management Expenses - Management expense ratio increased by 0.22 percentage points to 1.66%, attributed to the expansion of logistics personnel and depreciation from the Jinan and Yantai pharmaceutical modern logistics projects reaching operational status [2] Group 4: Coverage and Network - The company boasts the most comprehensive sales network in the province, with coverage rates exceeding 98% for large hospitals and 95% for grassroots medical institutions, achieving 100% coverage for tertiary hospitals [2] - Through distribution clients, the company has achieved coverage in hospitals and retail markets not directly covered in the province [2]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥7.55 billion, a decrease of 40.59% compared to ¥12.71 billion in the same period last year[23]. - The net profit attributable to shareholders was approximately ¥58.99 million, down 48.95% from ¥115.56 million in the previous year[23]. - The net cash flow from operating activities was approximately ¥276.93 million, reflecting a decline of 53.62% compared to ¥597.05 million in the same period last year[23]. - The basic earnings per share decreased by 49.09% to ¥0.0392 from ¥0.0770 in the previous year[23]. - The company reported a significant decline in net profit excluding non-recurring gains and losses, which was approximately ¥3.84 million, down 71.26% from ¥13.37 million in the previous year[23]. - The company's revenue for the first half of 2022 was approximately ¥7.55 billion, a decrease of 40.59% compared to ¥12.71 billion in the same period last year, primarily due to the impact of COVID-19 and divestitures[47]. - Operating costs also decreased by 40.75% to approximately ¥6.23 billion from ¥10.52 billion, reflecting the decline in revenue[47]. - The company reported a net profit for the first half of 2022 of CNY 138,001,790.94, a decline of 54.1% from CNY 300,415,359.39 in the first half of 2021[141]. - The total comprehensive income for the first half of 2022 was CNY 92,914,535.85, a decrease of 28.0% from CNY 129,063,966.18 in the first half of 2021[148]. Strategic Direction - The company plans to gradually shift its business strategy from "pursuing breadth" to "pursuing precision," focusing on core markets such as Shandong and Beijing[30]. - The company will exit low-revenue markets and dispose of related subsidiaries to enhance service quality and market share in core areas[30]. - The company aims to enhance its core competitiveness and improve business quality through strategic adjustments and asset optimization[32]. - The company is actively pursuing innovation and exploring various marketing and service models to ensure profitability amid a highly competitive market[68]. - The company plans to expand its market presence through strategic partnerships and new product launches in the upcoming quarters[156]. Research and Development - Research and development investment increased significantly by 116.98% to approximately ¥7.20 million, driven by investments in rational drug use software and traditional Chinese medicine research[47]. - The company aims to enhance its research and development efforts to innovate and improve its product offerings in the healthcare sector[161]. - The company is actively developing innovative traditional Chinese medicine products, including health foods and medical devices related to chronic disease treatment[43]. - The establishment of the Wang Qi Academy Fund aims to support research and development of innovative liquid traditional Chinese medicine[42]. - Research and development expenses for the first half of 2022 were reported at 105 million, indicating a focus on innovation despite the revenue decline[157]. Market Segments - The pharmaceutical distribution segment generated total revenue of 3.781 billion yuan, serving over 8,100 downstream customers nationwide[32]. - The medical diagnostics segment (IVD) reported sales revenue of 2.503 billion yuan, focusing on core markets like Shandong and Beijing[35]. - The comprehensive medical device segment achieved sales revenue of 1.185 billion yuan, optimizing product coverage and regional operations[34]. - The digital healthcare segment generated sales revenue of 37.83 million yuan, with over 35,000 users on its platforms serving nearly 23,000 downstream clients[37]. - The logistics segment has established a nationwide logistics network, including seven major transportation hubs, to provide customized third-party logistics services[38]. Financial Position - Total assets at the end of the reporting period were approximately ¥25.78 billion, a decrease of 2.32% from ¥26.40 billion at the end of the previous year[23]. - The accounts receivable amounted to CNY 9,436,600,229, representing 36.60% of total assets, a decrease of 2.36% from the previous year[52]. - Inventory decreased to CNY 1,711,173,630, accounting for 6.64% of total assets, down 1.19% from the previous year[52]. - The total liabilities decreased to ¥16,169,317,810.51 from ¥16,703,817,865.21, a reduction of approximately 3.2%[133]. - The equity attributable to shareholders decreased to ¥7,435,711,571.12 from ¥7,567,035,854.72, indicating a decline of about 1.7%[133]. Shareholder and Governance - The company does not plan to distribute cash dividends or issue bonus shares for this period[5]. - The company is committed to protecting shareholder rights and enhancing corporate governance structures[77]. - The company maintains a proactive approach to investor relations, ensuring transparent communication with stakeholders[78]. - The company emphasizes shareholder returns and aims to maximize investor interests by analyzing market conditions and adjusting development strategies[79]. - The company has not implemented any stock incentive plans or employee shareholding plans during the reporting period[74]. Operational Efficiency - The company is actively optimizing its product structure and reducing low-margin product distribution to enhance service quality and brand influence[32]. - The company has implemented an integrated supply chain management approach to optimize project lifecycle control and meet market demands for high quality and low cost[82]. - The company aims to improve operational efficiency and reduce costs by 10% in the next fiscal year[156]. - The company promotes a win-win cooperation model with partners, ensuring compliance with pricing policies and timely payments to suppliers[83]. Social Responsibility - The company is committed to environmental protection and sustainable development, implementing energy-saving measures and promoting resource recycling[84]. - The company actively engages in social welfare initiatives, encouraging employees to participate in charitable activities and supporting local economic development through tax contributions[85]. Legal and Compliance - The company reported a total litigation amount of 4,618.95 million yuan, with no significant impact on financial results[94]. - The company has no significant related party transactions during the reporting period[95]. - There were no major guarantees or entrusted financial management activities during the reporting period[106]. - The financial report for the first half of 2022 was not audited[129]. Accounting and Financial Reporting - The financial statements are presented in yuan[130]. - The company uses RMB as its functional currency for financial reporting[173]. - The company has established a robust framework for accounting treatment of business combinations under common control and non-common control[174]. - The company classifies financial assets into three categories: a) amortized cost, b) fair value through other comprehensive income, and c) fair value through profit or loss[188][190][191].

瑞康医药集团股份有限公司 2022 年第一季度报告全文 证券代码：002589 证券简称：瑞康医药 公告编号：2022-034 瑞康医药集团股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 4,093,497,042.67 | 5,764,538,064.30 | -28.99% | | 归属于上市公司股东的净利润（元） | 42,736,596.17 | 81 ...

Financial Performance - The company's operating revenue for 2021 was ¥21,059,718,896.22, a decrease of 22.67% compared to ¥27,233,914,391.79 in 2020[19] - The net profit attributable to shareholders for 2021 was ¥131,178,285.52, reflecting a decline of 49.80% from ¥261,302,746.74 in 2020[19] - The basic earnings per share for 2021 was ¥0.09, down 50.00% from ¥0.21 in 2020[19] - The total revenue for 2021 was approximately ¥21.06 billion, a decrease of 22.67% compared to ¥27.23 billion in 2020[54] - Net profit for the year was 1.38 billion yuan, down 38.91% compared to the previous year[42] - The company achieved total revenue of 21.06 billion yuan in 2021, a decrease of 22.67% year-on-year[41] - The company reported a significant increase in non-recurring losses, with a net profit excluding non-recurring items at -¥229,425,703.00 for 2021[19] Cash Flow and Assets - The net cash flow from operating activities increased by 6.75% to ¥442,952,611.75 in 2021, compared to ¥414,955,826.06 in 2020[19] - The total assets at the end of 2021 were ¥31,290,194,324.55, a decrease of 17.86% from ¥38,000,000,000 in 2020[20] - The company reported a total of 253 subsidiaries included in the consolidation scope as of December 31, 2021, with 34 new subsidiaries added during the year[62] - The company experienced a 29.60% decrease in inventory levels, totaling approximately ¥2.07 billion[59] - The total financial assets amounted to 767,054,168.00, with a significant portion being derivative financial assets valued at 158,554,367.00[76] Business Segments - The drug distribution segment generated revenue of 13.57 billion yuan, serving over 30,000 downstream customers[42] - The medical device segment reported sales of 2.41 billion yuan, expanding its business to over 20 provinces with more than 50 subsidiaries[44] - The IVD segment achieved sales revenue of 4.90 billion yuan, directly serving over 2,400 clients across various diagnostic fields[45] - The digital healthcare segment generated nearly 86.88 million yuan in sales, covering over 4,000 commercial insurance clients[48] - The pharmaceutical and medical device segment accounted for 99.50% of total revenue, with a revenue of approximately ¥20.95 billion, down 22.76% from ¥27.13 billion in 2020[54] Strategic Initiatives - The company aims to transition from a distribution model to a service-oriented model, focusing on building a smart supply chain and providing integrated "medicine + healthcare" solutions[38] - The company is actively exploring innovations in traditional Chinese medicine and developing terminal service and sales systems in this field[38] - The company plans to enhance its supply chain services through modern information technology and smart devices, aiming to reduce operational costs and improve efficiency[36] - The company is committed to becoming "the most dynamic integrator of pharmaceutical health ecosystem resources in China" through steady development across various business segments[89] - The company plans to invest 100 million RMB in technology upgrades to support its digital transformation initiatives[115] Management and Governance - The company has a well-defined compensation and performance evaluation system to attract and retain talent[132] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 5.29 million[121] - The company has maintained a consistent leadership structure with several long-term executives remaining in their roles[102] - The company emphasizes the importance of protecting shareholders' rights and has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and management team[148] - The company strictly adheres to information disclosure obligations, ensuring that shareholders and creditors are informed of operational dynamics and financial status in a timely and accurate manner[149] Market Trends and Challenges - The pharmaceutical distribution market in China is expected to see a steady growth trend, with health consumption becoming a rigid demand due to factors like aging population and increased health awareness[31] - The ongoing healthcare reforms and policies are expected to further impact the pharmaceutical industry, leading to a reshaping of market dynamics and increased competition[31] - The company faces risks from ongoing national healthcare reform policies, which may lead to price declines in pharmaceuticals and medical devices, impacting market growth[90] - The industry is experiencing a trend of accelerated consolidation, with policies promoting innovation and service improvements, leading to a higher concentration in the pharmaceutical sector[31] Research and Development - R&D expenses increased by 29.72% to approximately ¥11.56 million in 2021, primarily due to increased investment in mobile healthcare software development[66] - The number of R&D personnel increased by 15.56% to 52 in 2021, with a notable rise in the proportion of personnel holding bachelor's degrees[68] - The company plans to develop innovative liquid herbal medicine products through a newly established fund in collaboration with academic experts[52] Acquisitions and Divestments - The company completed an acquisition of a local healthcare firm for RMB 300 million, expected to enhance its service offerings and market presence[116] - The company acquired 90.36% equity in Shandong Lekang Jinyue Co., Ltd. during the reporting period[140] - The company reported a net loss of ¥293,677.20 from the acquisition of Ruichen (Tianjin) Pharmaceutical Co., Ltd. and a net loss of ¥1,156,875.31 from Qingdao Longhai Kangdong Pharmaceutical Co., Ltd.[167] - The company has ongoing litigation involving a total amount of 48,008.64 million yuan, with a judgment already made and 13,258.76 million yuan recovered during the reporting period[173] Shareholder Information - The total number of shares is 1,504,710,471, with 76.22% being unrestricted shares and 23.78% being restricted shares[197] - The number of shareholders at the end of the reporting period is 64,380, with significant shareholders including Zhang Renhua holding 18.14% and Han Xu holding 12.46%[199] - The company has a repurchase account holding 30,398,300 shares, representing 2.02% of the total share capital[200] - The company has not issued any new shares or conducted any stock splits during the reporting period[198] Social Responsibility and Sustainability - The company is committed to environmental protection and sustainable development, recognizing quality and safety as core responsibilities[154] - The company implemented energy-saving measures and established a target decomposition system for energy conservation, promoting a culture of saving among employees[155] - The company actively engages in social welfare initiatives, encouraging employees to participate in charitable activities and contributing to local economic development through increased tax payments[155]